STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Acquires 249,503 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 249,503 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were bought at an average price of $16.64 per share, with a total value of $4,151,729.92. Following the completion of the transaction, the insider now owns 11,953,198 shares of the company’s stock, valued at approximately $198,901,214.72. The trade was a 2.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The shares were purchased at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. bought 23,000 shares of STAAR Surgical stock. The stock was purchased at an average cost of $24.33 per share, with a total value of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. purchased 53,500 shares of STAAR Surgical stock. The shares were acquired at an average cost of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Price Performance

STAAR Surgical stock opened at $16.47 on Tuesday. The stock has a market cap of $812.38 million, a PE ratio of -40.17 and a beta of 0.62. The stock’s fifty day moving average is $21.55 and its two-hundred day moving average is $27.18. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Institutional Investors Weigh In On STAAR Surgical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Arcadia Investment Management Corp MI acquired a new position in STAAR Surgical in the third quarter valued at approximately $37,000. Quarry LP purchased a new stake in shares of STAAR Surgical during the 3rd quarter worth approximately $50,000. Quest Partners LLC acquired a new position in shares of STAAR Surgical in the 3rd quarter valued at $128,000. Van ECK Associates Corp boosted its holdings in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after buying an additional 393 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in STAAR Surgical during the 4th quarter worth $180,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. Mizuho lowered STAAR Surgical from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $45.00 to $17.00 in a research report on Wednesday, February 12th. BTIG Research cut STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $28.00 price target on shares of STAAR Surgical in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, STAAR Surgical has an average rating of “Hold” and an average price target of $26.86.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.